Answers are grounded in this paper and cite their sources.
Structure-based rational design led to the discovery of novel inhibitors of the MDM2-p53 protein-protein interaction. The affinity of these compounds for MDM2 was improved through conformational control of both the piperidinone ring and the appended N-alkyl substituent. Optimization afforded 29 (AM-8553), a potent and selective MDM2 inhibitor with excellent pharmacokinetic properties and in vivo efficacy.
No takes yet. Share an insight, caveat, or question.
Rew et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: